Seton Pharmaceuticals, LLC and Senores Pharmaceuticals on 17 March 2022 announced the launch of Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of the reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, in the US market. The product will be distributed by Seton Pharmaceuticals.
Butalbital, Acetaminophen and Caffeine Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.
“We are pleased to collaborate with Seton Pharmaceuticals for the commercial launch of Butalbital, Acetaminophen and Caffeine Capsules in the U.S. market” stated Dhananjay Barot, Director, Senores Pharmaceuticals. “Our unfaltering adherence towards the pharmaceutical industry makes us a major supplier for this product” stated Swapnil Shah, managing director, Senores Group.
“Seton is proud to partner with Senores on the launch of Butalbital, Acetaminophen and Caffeine Capsules” stated Christopher McCarthy, executive vice-president of Seton Pharmaceuticals. “This continues our commitment to providing affordable medicines to the consumer through quality manufacturing partnerships.”
US annual market size for Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg was approximately US$29.18 million (approximately Rs 222 crore).
